zoledronic acid (zoledronate)

Subscribe to Selected New Research on zoledronic acid

682 relevant articles (107 outcomes, 200 trials/studies) found for this Drug

Description: a potent inhibitor of bone resorption; structure given in first source

Also Known As:

zoledronate; Zometa; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid; CGP 42'446; CGP 42446A; CGP-42'446; CGP-42446; Novartis brand of zoledronic acid

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Organophosphorus Compounds: 126

Diphosphonates: 2715

zoledronic acid: 682

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Imidazoles: 94

zoledronic acid: 682

Experts

1.	Coleman, Robert E: 14 articles (08/2008 - 12/2002)
2.	Saad, Fred: 14 articles (07/2008 - 10/2002)
3.	Lipton, Allan: 10 articles (09/2008 - 08/2003)
4.	Santini, Daniele: 10 articles (02/2008 - 08/2003)
5.	Tonini, Giuseppe: 10 articles (02/2008 - 08/2003)
6.	Vincenzi, Bruno: 9 articles (02/2008 - 08/2003)
7.	Coleman, R E: 8 articles (01/2006 - 01/2000)
8.	Zheng, Ming: 8 articles (08/2005 - 08/2003)
9.	Major, Pierre: 6 articles (07/2008 - 01/2002)
10.	Smith, Matthew R: 6 articles (03/2008 - 06/2003)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/2004 - "Zoledronic acid was significantly more effective than placebo on most efficacy measures in patients with bone metastases secondary to other solid tumours (e.g" 04/01/2003 - "However, a more potent bisphosphonate, zoledronic acid (4 mg administered by 15-minute intravenous infusion), was approved for use and has improved efficacy in patients with bone metastases" 12/01/2002 - "Zoledronic acid is the first and only bisphosphonate to be proved effective in patients with all types of bone lesions, from osteolytic to osteoblastic, and therefore represents an important therapeutic advancement in the treatment of bone metastases." 02/01/2005 - "Zoledronic acid is the only bisphosphonate that has demonstrated efficacy for preventing skeletal complications in patients with HRPC and bone metastases" 05/01/2008 - "Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases." Get all the results and reference details, order at left...
2.	Prostatic Neoplasms (Prostate Cancer) 03/01/2007 - "CONCLUSION: Zoledronic acid (4 mg intravenously every 3 months) was safe and effective in preventing bone loss and reducing bone turnover in patients with prostate cancer when initiated during the first year of androgen deprivation therapy; patients with low baseline BMD experienced the greatest benefit." 10/01/2002 - "The objective of this study was to evaluate the efficacy of zoledronate in limiting the formation and/or progression of osteoblastic lesions produced by the injection of known prostate cancer cells (LAPC-9 and PC-3 cells) into the tibia of SCID mice" 05/01/2008 - "MATERIALS AND METHODS: A nationwide, observational, prospective, open and multi-centre trial was devised, with a total of 218 male patients diagnosed with prostate cancer at the HS stage (36%) or HI stage (64%) who were administered zoledronic acid (4 mg/IV/month for 6 months) in addition to their specific oncological treatment" 03/01/2007 - "PURPOSE: The aim of this study was to evaluate the efficacy and safety of zoledronic acid compared with placebo in preventing bone mineral density (BMD) loss and suppressing bone markers when initiated during the first year of androgen deprivation therapy in patients with locally advanced prostate cancer" 01/01/2005 - "The therapeutic potential of zoledronic acid for the treatment of prostate cancer has been demonstrated in both preclinical and clinical studies" Get all the results and reference details, order at left...
3.	Neoplasms (Cancer) 08/01/2007 - "PURPOSE: On the basis of stimulating data on animals reporting that weekly regimens of zoledronic acid (ZA) were effective in reducing skeletal tumor burden, we designed a study on humans to investigate the potential antiangiogenic role of a weekly low-dose therapy with ZA in patients with malignancies" 10/15/2005 - "The efficacy of zoledronic acid on primary bone tumors has not been investigated" 04/01/2008 - "CONCLUSION: In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ" 11/01/2006 - "study is a retrospective analysis of all patients who received zoledronic acid at Fox Chase Cancer Center, Philadelphia, Pa, between 1/10/02 and 1/30/04" 01/01/2005 - "Zoledronic acid, a third-generation BP with a favourable efficacy/safety record, was shown by ongoing large clinical trials to not only prevent or reduce CTIBL in early stage cancer, but to actually increase BMD" Get all the results and reference details, order at left...
4.	Breast Neoplasms (Breast Cancer) 02/01/2008 - "The aim of the present study was to investigate the therapeutic efficacy of zoledronate in reducing persistence of ITC in the bone marrow of patients with breast cancer after they had completed primary therapy" 02/01/2008 - "Our data provide the basis for investigating the efficacy of zoledronate on ITC in treating primary breast cancer in prospectively randomized trials" 08/01/2003 - "In vitro studies have provided important clues as to the molecular mechanisms by which zoledronic acid induces apoptosis of human breast cancer cell lines" 01/01/2003 - "In the multiple event analysis in a 12-month extension study (total study duration was 25 months) in patients with breast cancer, zoledronic acid was superior to pamidronic acid, with an 18% reduction in the risk of experiencing an SRE" 01/01/2009 - "In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients." Get all the results and reference details, order at left...
5.	Multiple Myeloma 12/01/2007 - "Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma." 01/01/2008 - "Similarly, in a separate 5-year trial, the overall survival of patients with multiple myeloma was greater in patients whose standard treatment regimens included zoledronic acid compared with standard treatment alone (P<0.01)" 04/01/2005 - "The aim of this study was to investigate the in vitro immunomodulatory effects of zoledronic acid (Zol) on peripheral blood Vgamma9/Vdelta2 (gammadelta) T cells of normal donors and multiple myeloma (MM) patients" 01/01/2008 - "MATERIALS AND METHODS: Between 2005 and 2006, we studied four patients with previous diagnosis of multiple myeloma treated with intravenous zoledronic acid, presenting nonhealing extraction sockets and intraoral exposed bone" 12/01/2007 - "Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient-derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo" Get all the results and reference details, order at left...
127 Diseases and 682 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	pamidronate (APD)
2.	zoledronic acid (zoledronate)
3.	Diphosphonates
4.	Hormones
5.	Clodronic Acid (Clodronate)
6.	Nitrogen
7.	docetaxel (Taxotere)
8.	ibandronic acid (Boniva)
9.	Alendronate (Alendronate Sodium)
10.	risedronic acid (risedronate)
305 Drugs and Important Bio-Agents and 397 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Distraction Osteogenesis
4.	Immunotherapy
5.	Heterologous Transplantation (Xenotransplantation)
25 Therapies and Procedures and 52 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>